## Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x
```

LOGINID: sssptau121zxn

```
PASSWORD:
```

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
                 Web Page URLs for STN Seminar Schedule - N. America
NEWS 1
NEWS 2
                 "Ask CAS" for self-help around the clock
                 EXTEND option available in structure searching
NEWS 3 May 12
                 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 4
         May 12
                 New UPM (Update Code Maximum) field for more efficient patent
NEWS
         May 27
                 SDIs in CAplus
NEWS
     6
         May 27
                 CAplus super roles and document types searchable in REGISTRY
NEWS
     7
         Jun 28
                 Additional enzyme-catalyzed reactions added to CASREACT
NEWS
                 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
      8
         Jun 28
                 and WATER from CSA now available on STN(R)
                 BEILSTEIN enhanced with new display and select options,
NEWS
     9
         Jul 12
                 resulting in a closer connection to BABS
                 BEILSTEIN on STN workshop to be held August 24 in conjunction
NEWS 10
         Jul 30
                 with the 228th ACS National Meeting
NEWS 11
        AUG 02
                 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                 fields
NEWS 12
         AUG 02
                 CAplus and CA patent records enhanced with European and Japan
                 Patent Office Classifications
NEWS 13
         AUG 02
                 STN User Update to be held August 22 in conjunction with the
                 228th ACS National Meeting
                 The Analysis Edition of STN Express with Discover!
NEWS 14
         AUG 02
                 (Version 7.01 for Windows) now available
                 Pricing for the Save Answers for SciFinder Wizard within
NEWS 15
         AUG 04
                 STN Express with Discover! will change September 1, 2004
                 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 16
         AUG 27
                 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
NEWS 17
         AUG 27
                 status data from INPADOC
         SEP 01
                 INPADOC: New family current-awareness alert (SDI) available
NEWS 18
                 New pricing for the Save Answers for SciFinder Wizard within
NEWS 19
         SEP 01
                 STN Express with Discover!
NEWS 20
         SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS EXPRESS
              JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 10:52:12 ON 08 SEP 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL SESSION

24

FULL ESTIMATED COST

ENTRY 0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:52:17 ON 08 SEP 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 SEP 2004 HIGHEST RN 741217-26-5 DICTIONARY FILE UPDATES: 7 SEP 2004 HIGHEST RN 741217-26-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=>

Uploading C:\STNEXP4\QUERIES\10660936.str

chain nodes : 19 21 23 24

ring nodes :

L 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

3-19 5-14 12-21 17-23 23-24

## 10/660,936

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18

14-15 15-16 16-17 17-18

exact/norm bonds :

12-21 17-23 23-24

exact bonds : 3-19 5-14

normalized bonds :

isolated ring systems :

containing 1 : 7 : 13 :

## Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS 23:CLASS 24:CLASS

## L1STRUCTURE UPLOADED

=> dis 11

L1 HAS NO ANSWERS

L1STR

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sam

SAMPLE SEARCH INITIATED 10:52:39 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

> BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:

257 TO 903

PROJECTED ANSWERS:

1 TO 80

L2

1 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 10:52:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 700 TO ITERATE

100.0% PROCESSED 700 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01

L3 28 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY 155.42 SESSION 155.63

155.42

FILE 'CAPLUS' ENTERED AT 10:52:50 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2004 VOL 141 ISS 11 FILE LAST UPDATED: 7 Sep 2004 (20040907/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 198 L3

=> s 13 and pd<oct 1999

198 L3

19681062 PD<OCT 1999

(PD<19991000)

L5 4 L3 AND PD<OCT 1999

=>

L1

(FILE 'HOME' ENTERED AT 10:52:12 ON 08 SEP 2004)

FILE 'REGISTRY' ENTERED AT 10:52:17 ON 08 SEP 2004

STRUCTURE UPLOADED

L2 1 S L1 SAM

L3 28 S L1 FULL

FILE 'CAPLUS' ENTERED AT 10:52:50 ON 08 SEP 2004

L4 198 S L3

L5 4 S L3 AND PD<OCT 1999

=> dis 15 1-4 bib abs hitstr

```
L5
     ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN
     1999:594916 CAPLUS
DN
     131:209130
ΤI
     Combination therapy and composition using an antiplatelet agent and a
     COX-2 inhibitor for acute coronary ischemic syndrome and related
     conditions
IN
     Nichtberger, Steven A.
PA
     Merck & Co., Inc., USA
     PCT Int. Appl., 55 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                            APPLICATION NO.
                                                                   DATE
     -----
                         - - - -
                                                                   -----
     WO 9945913
PΙ
                          A1
                                19990916
                                            WO 1999-US5063
                                                                   19990309 <--
        W: CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     CA 2322824
                          AA
                                19990916
                                            CA 1999-2322824
                                                                    19990309 <--
     EP 1061908
                          Α1
                                20001227
                                            EP 1999-911208
                                                                    19990309
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, LT, LV, FI, RO
     JP 2002506024
                          T2
                                20020226
                                            JP 2000-535328
                                                                    19990309
     US 6136804
                          Α
                                20001024
                                            US 1999-267287
                                                                   19990312
     US 6511968
                                            US 2000-694212
                          B1
                                20030128
                                                                   20001023
PRAI US 1998-77900P
                          P
                                19980313
     GB 1998-15857
                          Α
                                19980721
                          W
     WO 1999-US5063
                                19990309
     US 1999-267287
                          А3
                                19990312
     A method for treating, preventing, or reducing the risk of developing a
AΒ
     condition selected from acute coronary ischemic syndrome, thrombosis,
     thromboembolism, thrombotic occlusion and reocclusion, restenosis,
     transient ischemic attack, and first or subsequent thrombotic stroke, in a
     patient comprises administering to the patient a therapeutically effective
     amount of an antiplatelet agent in combination with a therapeutically
     effective amount of a COX-2 inhibitor. The invention also provides a
     pharmaceutical composition comprising a therapeutically effective amount of a
     COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an
     antiplatelet agent, or a pharmaceutically acceptable salt thereof.
IT
     202409-33-4
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
        (antiplatelet agent-cyclooxygenase-2 inhibitor combination for
        treatment of acute coronary ischemic syndrome and related conditions)
RN
     202409-33-4 CAPLUS
CN
     2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI)
     (CA INDEX NAME)
```

included.

202409-33-4P

IT

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
L5
AN
     1999:282039 CAPLUS
DN
     130:306593
ΤI
     Combination therapy using a HMG-CoA reductase inhibitor and a
     cyclooxygenase-2 (COX-2) inhibitor for reducing the risks associated with
     cardio- and cerebrovascular disease
IN
     Winokur, Melvin
     Merck & Co., Inc., USA
PA
SO
     PCT Int. Appl., 55 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                         KIND
                                DATE
                                             APPLICATION NO.
                                                                    DATE
     ------
                                -----
                                             -----
PI
     WO 9920110
                          A1
                                19990429
                                            WO 1998-US21901
                                                                    19981016 <--
         W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE,
             HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG,
             MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2306646
                                19990429
                          AA
                                            CA 1998-2306646
                                                                    19981016 <--
     AU 9913612
                          A1
                                19990510
                                            AU 1999-13612
                                                                    19981016 <--
     AU 753657
                          B2
                                20021024
    · EP 1024696
                          A1
                                20000809
                                            EP 1998-957328
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, LT, LV, FI, RO
     JP 2001520174
                          T2
                                20011030
                                            JP 2000-516533
                                                                    19981016
     US 6245797
                          B1
                                20010612
                                            US 1998-179349
                                                                    19981020
PRAI US 1997-62691P
                          ₽
                                19971022
     GB 1998-6688
                          Α
                                19980327
     WO 1998-US21901
                          W
                                19981016
     The invention provides a drug combination comprised of a HMG-CoA reductase
AB
     inhibitor in combination with a COX-2 inhibitor, which is useful for
     treating, preventing, and/or reducing the risk of developing
     atherosclerosis and atherosclerotic disease events. Preparation of selected
     COX-2 inhibitors, e.g. 5-chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-
     pyridinyl)pyridine, is described. Pharmaceutical formulations are
```

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (HMG-CoA reductase inhibitor combination with COX-2 inhibitor for reducing risks associated with cardio- and cerebrovascular disease, COX-2 inhibitor preparation, and pharmaceutical formulations) 202409-33-4 CAPLUS

2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RN

CN

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:710173 CAPLUS

DN 130:52303

TI 2-Pyridinyl-3-[4-(methylsulfonyl)phenyl]pyridines: selective and orally active cyclooxygenase-2 inhibitors

AU Friesen, Richard W.; Brideau, Christine; Chan, Chi Chung; Charleson, Stella; Deschenes, Denis; Dube, Daniel; Ethier, Diane; Fortin, Rejean; Gauthier, Jacques Yves; Girard, Yves; Gordon, Robert; Greig, Gillian M.; Riendeau, Denis; Savoie, Chantal; Wang, Zhaoyin; Wong, Elizabeth; Visco, Denise; Xu, Li Jing; Young, Robert N.

CS Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, QC, H9R 4P8, Can.

SO Bioorganic & Medicinal Chemistry Letters (1998), 8(19), 2777-2782

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

GΙ

AB The title compds. were prepared and evaluated for their ability to inhibit the isoenzymes of cyclooxygenase, COX-1 and COX-2. Optimum COX-2 activity was observed by introduction of a substituent at C5 of the central pyridine. Pyridine derivative I was identified as the optimum compound in this series.

IT 202409-33-4P 202409-41-4P

202409-33-4P 202409-41-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(2-pyridinyl-3-[4-(methylsulfonyl)phenyl]pyridines as cyclooxygenase-2 inhibitors)

RN 202409-33-4 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 202409-41-4 CAPLUS CN 2,3'-Bipyridine, 5-chloro-6'-ethyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1998:87712 CAPLUS
- DN 128:140614
- TI Preparation of substituted pyridines as selective cyclooxygenase-2 inhibitors
- IN Dube, Daniel; Fortin, Rejean; Friesen, Richard; Wang, Zhaoyin; Gauthier, Jacques Yves
- PA Merck Frosst Canada Inc., Can.; Dube, Daniel; Fortin, Rejean; Friesen,

Richard; Wang, Zhaoyin; Gauthier, Jacques Yves

SO PCT Int. Appl., 88 pp. CODEN: PIXXD2 DT Patent LA English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE -----\_ \_ \_ \_ \_\_\_\_\_ -----\_\_\_\_\_\_ PΤ WO 9803484 A1 19980129 WO 1997-CA486 19970708 <--W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, MI, MD, NE, SN, TD, TG GN, ML, MR, NE, SN, TD, TG CA 2260016 AΑ 19980129 CA 1997-2260016 19970708 <--CA 2412968 AA 19980129 CA 1997-2412968 19970708 <--AU 9733319 **A1** 19980210 AU 1997-33319 19970708 <--AU 723179 B2 20000817 EP 912518 A1 19990506 EP 1997-929067 19970708 <--EP 912518 B1 20030910 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO CN 1225085 Α 19990804 CN 1997-196377 19970708 <--BR 9710372 Α 19990817 BR 1997-10372 19970708 <--JP 11514008 T2 19991130 JP 1997-506397 19970708 NZ 333230 A 20000825 NZ 1997-333230 19970708 JP 3251945 B2 JP 1998-506397 20020128 19970708 JP 2002080453 A2 JP 2001-209904 20020319 19970708 EE 3680 В1 20020415 EE 1999-18 19970708 IL 127441 A1 IL 1997-127441 20030212 19970708 SK 283261 B6 20030401 SK 1999-36 19970708 AT 249437 Е AT 1997-929067 20030915 19970708 CZ 292843 В6 20031217 CZ 1999-130 19970708 PT 912518 Т 20031231 PT 1997-929067 19970708 ES 2205242 Т3 ES 1997-929067 20040501 19970708 US 5861419 19990119 Α US 1997-893395 19970711 <--TW 453994 В TW 1997-86110013 20010911 19970715 ZA 9706335 Α 1998,0318 ZA 1997-6335 19970717 <--HR 970389 В1 20021031 HR 1997-970389 19970717 US 6001843 Α US 1998-181887 19991214 19981029 NO 9900191 Α 19990316 NO 1999-191 19990115 <--US 1999-312790 US 6071936 Α 20000606 19990517 US 2003065011 Α1 US 2001-21187 20030403 20011030 US 6596736 B2 20030722 US 2004029921 Α1 20040212 US 2003-395788 20030324 PRAI US 1996-22128P Ρ 19960718 GB 1996-16126 Α 19960801 US 1996-27139P P 19961001 GB 1996-21420 Α 19961015 US 1997-41814P Ρ 19970408 GB 1997-9291 Α 19970507 CA 1997-2260016 Α3 19970708 JP 1998-506397 A3 19970708 WO 1997-CA486 W 19970708 US 1997-893395 A3 19970711 US 1998-181887 A3 19981029 US 1999-312790 A1 19990517 US 2000-570191 Α3 20000515

US 2001-21187 MARPAT 128:140614 A3 20011030

Ι

OS GI

$$R^2$$
 $Ar$ 

The title compds. [I; R1 = Me, NH2, NHC(O)CF3, NHMe; Ar = (un)substituted Ph, pyridyl (or the N-oxide thereof); R2 = halo, C1-6 alkoxy, C1-6 alkylthio, etc.], useful for treating antiinflammatory diseases comprising, were prepared Thus, reaction of 2-bromo-3-(4-methylsulfonyl)phenyl-5-trifluoromethylpyridine with di-Et 3-pyridylborane in the presence of PdBr2(PPh3)2 and Na2CO3 in PhH/EtOH afforded I [R1 = Me; R2 = CF3; Ar = 3-pyridyl] which showed IC50 of 1.8 μM against COX-2 (whole blood) vs. IC50 of 5 μM against COX-1 (U937).

IT 202409-33-4P 202409-41-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of substituted pyridines as selective cyclooxygenase-2 inhibitors)

RN 202409-33-4 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 202409-41-4 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-6'-ethyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

IT 202409-40-3P 202409-42-5P 202409-44-7P 202409-61-8P 202409-63-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyridines as selective cyclooxygenase-2 inhibitors)

RN 202409-40-3 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 202409-42-5 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-6'-ethyl-3-[4-(methylsulfonyl)phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 202409-41-4

CMF C19 H17 Cl N2 O2 S

CM 2

CRN 75-75-2 CMF C H4 O3 S

RN 202409-44-7 CAPLUS

CN 2,3'-Bipyridine, 5-chloro-2',6'-dimethyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 202409-61-8 CAPLUS

CN 2,3'-Bipyridine, 5-fluoro-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RN 202409-63-0 CAPLUS CN 2,3'-Bipyridine, 5-bromo-6'-methyl-3-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 10:52:12 ON 08 SEP 2004)

log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	22.50	178.13
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.80	-2.80

STN INTERNATIONAL LOGOFF AT 10:54:54 ON 08 SEP 2004